Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

Prescription Demand Growth Continues in the Third Quarter 2021 with a 61% Increase in Twirla Cycles Dispensed

Agile Therapeutics Reports Third Quarter 2021 Financial Results

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021

Agile Therapeutics continues to trade under intense selling pressure. This selling amplified after the company announced a sizeable offering.

Agile Therapeutics: Bullish On Capitulation And Max Pain

Adamis Pharmaceuticals

Denison Mines

If you're making a penny stocks watchlist right now, check these three small-caps out The post Top Penny Stocks to Watch Making Big Moves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch Making Big Moves Right Now

The stock price of Agile Therapeutics Inc (NASDAQ: AGRX) fell over 20% this past week. This is why it happened.

AGRX Stock: Why It Fell This Past Week

Kintara Therapeutics

Progenity

Sesen Bio Inc.

Looking for biotech penny stocks to watch on Reddit? Check these four out for your list The post Best Biotech Penny Stocks on Reddit to Buy Now?

Best Biotech Penny Stocks on Reddit to Buy Now? 4 For Your Watchlist

PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Josephine Torrente has been appointed to the Company's board of directors, as a Class II director, effective as of October 7, 2021. Ms. Torrente will serve on Agile's Science and Technology Committee and Nominating and Corporate Governance Committee.

Agile Therapeutics Appoints Josephine Torrente to its Board of Directors

PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0.85 per one share of common stock and one-half of a warrant to purchase one share of common stock. The warrants have an exercise price of $0.85 per share of common stock, are exercisable immediately, and will expire five years from the date of issuance. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $22,666,650. All securities in the offering will be sold by Agile Therapeutics.

Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants

PRINCETON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics.   The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021 Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021

Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary

PRINCETON, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following virtual investor conferences during the month of September 2021.

Agile Therapeutics to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth service, which will establish the first telehealth relationship for Agile and offer an additional point of access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in a fast-growing channel.

Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women's Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system

Agile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company's flagship product, Twirla, is already starting to display impressive growth trends. The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position.

Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy

Minim

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

2 Penny Stocks Insiders Are Buying

Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q2 2021 Results - Earnings Call Transcript

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 4.76% and -18.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Agile Therapeutics (AGRX) Reports Q2 Loss, Lags Revenue Estimates

Shares of Agile Therapeutics (NASDAQ:AGRX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 66.67% year over year to ($0.20), which beat the estimate of ($0.21).

Agile Therapeutics: Q2 Earnings Insights

Total Prescriptions (TRx) Grew 171% in Second Quarter

Agile Therapeutics Reports Second Quarter 2021 Financial Results

Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT

Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021

PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the company will be participating virtually in the William Blair 41st Annual Growth Stock Conference.

Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference

Agile Therapeutics recently reported a mixed Q1 earnings with a slight beat on EPS and a miss on revenue. However, the company's earnings call has reignited my bullish outlook. Q1 was Twirla's first quarter on the market and its sales numbers were not very impressive. Consequently, the market has pressured AGRX to a new 52-week low.

Agile Therapeutics: Returning To Bullish Outlook After Encouraging Q1 Earnings

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2021 Results - Earnings Call Transcript

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 9.09% and -82.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Agile Therapeutics (AGRX) Reports Q1 Loss, Lags Revenue Estimates

Shares of Agile Therapeutics (NASDAQ:AGRX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 100.00% year over year to ($0.20), which beat the estimate of ($0.21).

Recap: Agile Therapeutics Q1 Earnings

Prescription Growth Reflects Increasing Demand for Twirla

News for Agile Therapeutics Stock (AGRX)